195 related articles for article (PubMed ID: 17367853)
1. Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency.
Aladağ E; Aksu S; Demiroğlu H; Sayınalp N; Göker H; Haznedaroğlu İC; Özcebe Oİ; Büyükaşık Y
Turk J Med Sci; 2019 Oct; 49(5):1560-1563. PubMed ID: 31652037
[TBL] [Abstract][Full Text] [Related]
2. Portal hypertension and ascites in extramedullary hematopoiesis.
Amarapurkar P; Parekh S; Amarapurkar A; Amarapurkar D
J Clin Exp Hepatol; 2012 Jun; 2(2):188-90. PubMed ID: 25755427
[TBL] [Abstract][Full Text] [Related]
3. Novel germline JAK2
Song J; Lanikova L; Kim SJ; Papadopoulos N; Meznarich J; Constantinescu SN; Parsegov B; Prchal JF; Prchal JT
Am J Hematol; 2024 Apr; ():. PubMed ID: 38629639
[TBL] [Abstract][Full Text] [Related]
4. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.
Tefferi A; Thiele J; Vannucchi AM; Barbui T
Leukemia; 2014 Jul; 28(7):1407-13. PubMed ID: 24441292
[TBL] [Abstract][Full Text] [Related]
5. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
Tefferi A; Lasho TL; Finke CM; Knudson RA; Ketterling R; Hanson CH; Maffioli M; Caramazza D; Passamonti F; Pardanani A
Leukemia; 2014 Jul; 28(7):1472-7. PubMed ID: 24402162
[TBL] [Abstract][Full Text] [Related]
6. Gain of function in Jak2
Nishanth G; Wolleschak D; Fahldieck C; Fischer T; Mullally A; Perner F; Schnöder TM; Just S; Heidel FH; Schlüter D
Leukemia; 2017 Apr; 31(4):1000-1003. PubMed ID: 28074070
[No Abstract] [Full Text] [Related]
7. Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm.
Kalala F; Mamara A; Ioannou M; Speletas M
Hematol Rep; 2012 May; 4(2):e12. PubMed ID: 22826794
[TBL] [Abstract][Full Text] [Related]
8. Molecular aspects of myeloproliferative neoplasms.
Delhommeau F; Jeziorowska D; Marzac C; Casadevall N
Int J Hematol; 2010 Mar; 91(2):165-73. PubMed ID: 20186505
[TBL] [Abstract][Full Text] [Related]
9. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.
Hattori N; Fukuchi K; Nakashima H; Maeda T; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Gomi K; Tomoyasu S
Int J Hematol; 2008 Sep; 88(2):181-188. PubMed ID: 18612778
[TBL] [Abstract][Full Text] [Related]
10. Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia.
Ohyashiki K; Kiguchi T; Ito Y; Fujimoto H; Gotoh A; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
Int J Hematol; 2008 May; 87(4):446-448. PubMed ID: 18409076
[No Abstract] [Full Text] [Related]
11. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
14. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
15. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
16. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
